Long‐term follow‐up of chronic hepatitis C patients with sustained virological response to various forms of interferon‐based anti‐viral therapy

Formann, E.; Steindl–Munda, Petra; Hofer, Harald; Jessner, Wolfgang; Bergholz, U.; Gurguta, C.; Ferenci, Péter

doi:10.1111/j.1365-2036.2006.02785.x

Cited by 72 publications

(62 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Only in seven patients (<1%), HCV-RNA was detected (after 391-1076 days of treatment). All these data indicate that the late relapse after SVR in chronic hrpatits C patients following an IFN-based anti-viral therapy is rare [16][17][18][19] . This is the first study from Bangladesh on longterm outcomes of anti-viral therapy for chronic HCV infection.…”

Section: Discussionmentioning

confidence: 99%

Sustained virological response after treatment in patients with chronic hepatitis C infection - a five year follow up

Rahman

Ahmed

Masud

et al. 2013

Bangladesh Med Res Counc Bull

View full text Add to dashboard Cite

Peginterferon α-2a and ribavirin combination therapy achieves a sustained virological response (SVR) in patients with chronic hepatitis C. Little is know about long-term durability of hepatitis C virusRibonucleic acid (HCV-RNA) negativity in patient treated with pegylated interferon and ribavirin therapy. Aim of this study was to evaluate the durability of virologic response in patients with SVR to anti-viral therapy treated at our centre. A total of 52 patients with chronic hepatitis C virus infection who had obtained SVR after Peginterferon α-2a and ribavirin combination therapy were followed up to 5 years with annual HCV-RNA testing. During this follow up period, 4 of 52 patients with initial SVR developed late relapse of hepatitis C virus infection. Relapse was more common in patients who has cirrhosis (3/6 [50%]) vs (1/46 [2.17%]) without cirrhosis. In conclusion, SVR is durable in most patients, but some patients do have late relapse; long term follow up may be particularly important in a subset of patients with hepatitis C virus infection who have liver cirrhosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Sustained virological response after treatment in patients with chronic hepatitis C infection - a five year follow up

Rahman

Ahmed

Masud

et al. 2013

Bangladesh Med Res Counc Bull

View full text Add to dashboard Cite

show abstract

“…1,2,6 Studies have demonstrated that SVR is associated with histological improvement, assessed by liver biopsy, and with the prevention of complications, such as the development of liver cirrhosis and HCC. [11][12][13][14] Thus, SVR as result of therapy is deemed as an important factor for long-term favourable prognosis, although 4.0% to 8.7% of late recurrence was observed in two studies. Ferreira, Carneiro, Souza et al In addition, some clinical studies have indicated the occurrence of HCC cases in cirrhotic patients who had developed SVR after antiviral treatment, emphasizing the need to maintain HCC screening regardless of treatment response.…”

Section: Introductionmentioning

confidence: 99%

Long-term follow-up of patients with chronic hepatitis C with sustained virologic response to interferon

Ferreira¹,

Carneiro²,

Souza³

et al. 2010

Braz J Infect Dis

View full text Add to dashboard Cite

Background and aim:The durability of the sustained virologic response (SVR) in patients with chronic hepatitis C after treatment and the ideal follow-up time for these patients remains undefi ned. The objective of the study was to evaluate the durability of the virologic response in patients with chronic hepatitis C followed up for at least 12 months after SVR at HCFMRP-USP. Methods: The study was conducted on 174 patients with chronic hepatitis C treated with different antiviral regimens who had achieved SVR. Qualitative serum HCV-RNA was determined by the commercial kit (COBAS AMPLICOR HCV, v2.0). Results: There was predominance of male (73%) with a mean age of 45.6 ± 10 years. Liver cirrhosis was present in 16.1% of the study subjects. Mean follow-up time after SVR was 47 months (12-156 months). Twenty-two patients received monotherapy with interferon; 94 received interferon plus ribavirin, and 58 received pegylated interferon plus ribavirin. A total of 134 patients (77.0%) received one treatment course, 29 (16.7%) received two courses, and 11 (6.3%) received three courses. The distribution of HCV genotypes was: genotype 1 (40.2%), genotype 3 (40.8%) and genotype 2 (10.3%). Genotype was undetermined in 8.7% of cases. None of the 174 patients had recurrence of HCV infection. Two cirrhotic patients developed hepatocellular carcinoma (HCC) during follow-up. Conclusions: Among patients with SVR there was no recurrence of HCV infection or evidence of liver disease progression in any patient followed up for a mean of 47 months after SVR, except for patients with advanced hepatic disease before treatment, who may develop HCC despite SVR. Therefore, one can assume that SVR is associated with long term good prognosis.

show abstract

“…Among them, patients having prior appropriate treatment for HCC and no evidence of viable HCC at the start of antiviral therapy were enrolled. Patients with other liver disease such as chronic hepatitis B, a history of alcohol ingestion (≥30 g/day), human immunodeficiency virus infection, or obesity (body mass index ≥27 kg/m 2 of human recombinant erythropoietin (rEPO; Eprex ; Janssen Korea, Seoul, Korea) was given twice a week subcutaneously when absolute neutrophil count decreased to less than 500/mm 3 or hemoglobin level decreased to less than 8.0 g/dL, by the physician's discretion.…”

Section: Patientsmentioning

confidence: 99%

“…[2][3][4] Although treatment outcomes have evolved greatly since combination therapy was introduced to treat CHC, 5-7 antiviral treatment in patients with CHC-related HCC has rarely been reported. This study was aimed to evaluate the efficacy and safety of antiviral therapy in CHC patients after treatment for HCC.…”

Section: Introductionmentioning

confidence: 99%

“…1 However, it is well known that disease progression can be halted by achievement of a sustained virologic response (SVR) following antiviral therapy. [2][3][4] Although treatment outcomes have evolved greatly since combination therapy was introduced to treat CHC, [5][6][7] antiviral treatment in patients with CHC-related HCC has rarely been reported. This study was aimed to evaluate the efficacy and safety of antiviral therapy in CHC patients after treatment for HCC.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Antiviral Therapy in Patients after Treatment for Hepatitis C-Related Hepatocellular Carcinoma

Shin¹,

Paik²,

Gwak³

et al. 2011

Gut Liver

View full text Add to dashboard Cite

Background/Aims: Despite great progress, antiviral treatment for chronic hepatitis C in patients with prior hepatocellular carcinoma (HCC) has been rarely investigated. We evaluated the effi cacy and safety of antiviral therapy following treatment for hepatitis C-related HCC. Methods: Thirteen patients (age 34 to 60 years) who were treated with peginterferon plus ribavirin after treatment for HCC were reviewed. Results: There were 6 patients with genotype 1 and 7 patients with genotype 2. All patients showed advanced fi brosis (≥F3) but belonged to the Child-Pugh class A. Treatment was stopped in 2 patients because of recurrent HCC and in 1 patient due to a lack of early virologic response. Seven patients achieved sustained virologic response and three patients relapsed. The sustained virologic response rate was 54% overall, 17% in genotype 1, and 86% in genotype 2. No signifi cant adverse events were reported. Conclusions: Antiviral therapy should not be excluded in patients who were previously treated with HCC with genotype 2 chronic hepatitis C, in which an effi cacious antiviral treatment for chronic hepatitis C was feasible. Additional study is needed to prove the validity of antiviral therapy in patients with genotype 1 hepatitis C-related HCC. (Gut Liver 2011;5:77-81) Key Words: Chronic hepatitis C; Hepatocellular carcinoma; Peginterferon; Ribavirin INTRODUCTIONCirrhosis or hepatocellular carcinoma (HCC) develops in about a third of chronic hepatitis C (CHC) patients over a period of 20 years.1 However, it is well known that disease progression can be halted by achievement of a sustained virologic response (SVR) following antiviral therapy. [2][3][4] Although treatment outcomes have evolved greatly since combination therapy was introduced to treat CHC, 5-7 antiviral treatment in patients with CHC-related HCC has rarely been reported. This study was aimed to evaluate the efficacy and safety of antiviral therapy in CHC patients after treatment for HCC. MATERIALS AND METHODS PatientsThe medical records of 283 patients who received combination therapy with peginterferon (pegIFN) and ribavirin from May 2002 to July 2008 were reviewed. Among them, patients having prior appropriate treatment for HCC and no evidence of viable HCC at the start of antiviral therapy were enrolled. Patients with other liver disease such as chronic hepatitis B, a history of alcohol ingestion (≥30 g/day), human immunodeficiency virus infection, or obesity (body mass index ≥27 kg/m 2 ) were excluded. After or during antiviral treatment, alfa-fetoprotein combined with imaging study of a dynamic computed tomography or abdominal ultrasonography was checked every 3 months.One hundred eighty μg of pegIFN -2a (Pegasys ; Hoffmann-La Roche, Basel, Switzerland) once a week was injected subcutaneously. Ribavirin (Viramid ; Ilsung Pharmaceuticals Co., Seoul, Korea) was given orally twice daily at a dose of 1,000 mg/day for patients weighing 75 kg or less and 1,200 mg/day for those weighing more than 75 kg for genotype 1; 800 mg/ day was given f...

show abstract

Long‐term follow‐up of chronic hepatitis C patients with sustained virological response to various forms of interferon‐based anti‐viral therapy

Cited by 72 publications

References 36 publications

Sustained virological response after treatment in patients with chronic hepatitis C infection - a five year follow up

Sustained virological response after treatment in patients with chronic hepatitis C infection - a five year follow up

Long-term follow-up of patients with chronic hepatitis C with sustained virologic response to interferon

Antiviral Therapy in Patients after Treatment for Hepatitis C-Related Hepatocellular Carcinoma

Contact Info

Product

Resources

About